Head to Head Survey: Biogen (BIIB) and Its Peers


Biogen is one of 45 public companies in the "Biopharmaceuticals" industry, but how does it contrast to its peers? We will compare Biogen to similar companies based on the strength of its analyst recommendations, dividends, institutional ownership, profitability, earnings, valuation and risk. Biogen currently has a consensus target price of $329.27, suggesting a potential upside of 3.40%.



from Biotech News